Otani Naoko, Morishita Yoshiyuki, Oh Iekuni, Saito Osamu, Takemoto Fumi, Muto Shigeaki, Kusano Eiji
Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Japan.
Intern Med. 2012;51(11):1375-8. doi: 10.2169/internalmedicine.51.6555. Epub 2012 Jun 1.
We report a case of mesangial proliferative glomerulonephritis with interstitial nephritis associated with multicentric Castleman's disease (MCD) successfully treated with an anti-interleukin-6 receptor antibody (tocilizumab). This mesangial proliferative glomerulonephritis with interstitial nephritis was resistant to methylprednisolone treatment; however, it was markedly improved with tocilizumab, which was administered intravenously at a dose of 8 mg/kg every 2 weeks. These results suggest that tocilizumab is effective for the treatment of mesangial proliferative glomerulonephritis with interstitial nephritis associated with MCD.
我们报告了1例伴有间质性肾炎的系膜增生性肾小球肾炎合并多中心Castleman病（MCD）患者，该患者接受抗白细胞介素-6受体抗体（托珠单抗）治疗成功。这种伴有间质性肾炎的系膜增生性肾小球肾炎对甲泼尼龙治疗耐药；然而，使用托珠单抗后病情明显改善，托珠单抗以每2周8 mg/kg的剂量静脉给药。这些结果表明，托珠单抗对治疗伴有MCD的伴有间质性肾炎的系膜增生性肾小球肾炎有效。
